Laura A.Dahl

Staff Attorney

Chicago + 1.312.269.4265

Connect

Share

Laura Dahl's practice focuses on complex health care litigation matters. She has assisted in the representation of major pharmaceutical manufacturers in actions involving the federal False Claims Act and the Anti-Kickback Statute as well as various state false claims acts, consumer protection acts, and deceptive trade practice acts.

Laura is very active in pro bono matters. She drafts legislation and advises the Community Association Institute — Illinois Legislation Action Committee on legislative matters. She also represents individuals through National Immigrant Justice Center, Lawyers for the Creative Arts, and Cabrini Green Legal Aid. She has conducted seminars for not-for-profit organizations through the Community Economic Development Law Project.

Laura is a member of the American Bar Association, the Illinois State Bar Association, and The Chicago Bar Association.

Erfahrung

  • Celgene resolves False Claims Act case related to alleged off-label promotion of Thalomid® and Revlimid®Jones Day represented Celgene Corporation in a False Claims Act lawsuit related to allegations that Celgene promoted the cancer treatment drugs Thalomid® and Revlimid® for off-label uses prior to their FDA approval for such uses, and paid kickbacks to physicians in order to get them to promote and prescribe those drugs.
  • Cardinal Health acquires The Harvard Drug Group for $1.115 billionJones Day advised Cardinal Health in its acquisition of The Harvard Drug Group, a distributor of generic pharmaceuticals, over-the-counter medications, and related products to retail, institutional, and alternate care customers from Court Square Capital Partners for $1.115 billion.
  • Strong suppression motion results in prosecution's decision to drop highjacking chargeLocked up since May 2011, Mr. Mayes walked out of Cook County jail nearly a year later after he agreed to plead guilty to possession of a stolen motor vehicle, receiving a sentence of felony probation.
  • Pharmaceutical manufacturers prevail before the U.S. Supreme Court in dispute under 340B Drug Pricing ProgramJones Day, on behalf of TAP Pharmaceutical Products Inc. (now known as Takeda Pharmaceuticals North America, Inc.), along with counsel for co-defendants, prevailed before the U.S. Supreme Court.
  • Chevron obtains discovery against former opposing counsel in long-running litigation in Ecuador and BIT Arbitration against Republic of EcuadorJones Day client Chevron Corporation has been involved in contentious litigation in Ecuador in which the plaintiffs have alleged billions of dollars in damages.
  • Pharmaceutical and device manufacturers conduct compliance risk assessmentJones Day conducted a compliance risk assessment of two manufacturers' existing compliance programs.
  • Volunteers participate in 2009-10 Edward J. Lewis II Lawyers in Classroom ProgramJones Day Chicago has partnered with the Constitutional Rights Foundation Chicago (CRFC) to work with area students in the 7th and 8th grades to help them understand the U.S. Constitution and our legal system.
  • Abbott and TAP Pharmaceutical defend against Average Wholesale Price (AWP) litigationJones Day clients Abbott Laboratories and TAP Pharmaceutical Products, along with virtually the entire pharmaceutical industry, have been the subject of civil litigation alleging that drug manufacturers falsely reported the "average wholesale price," or "AWP," for various drugs in order to inflate the reimbursement paid by government and private payors for those drugs.
    •

    Fall 2012 Jones Day Publications

    Health Care Compliance and Enforcement Update

    Winter 2012 Jones Day Publications

    Health Care Compliance and Enforcement Update

    September 2011 Jones Day Publications

    Health Care Compliance and Enforcement Update

    • November 2015
      General Nonprofit Compliance: An Overview of Reporting and Record-keeping Requirements
    • May 2008
      Starting a Not-For-Profit Tax-Exempt Corporation

    Bitte beachten Sie vor dem Versenden:

    Die Informationen auf unserer Website sind für den allgemeinen Gebrauch und stellen keine Rechtsberatung dar. Der Versand dieser E-Mail ist nicht dazu bestimmt, ein Mandatsverhältnis zu begründen, und der Erhalt dieser E-Mail stellt kein Mandatsverhältnis dar. Alles, was Sie an jemanden in unserer Kanzlei senden, ist nicht vertraulich oder privilegiert, es sei denn, wir haben zugestimmt, Sie zu vertreten. Wenn Sie diese E-Mail versenden, bestätigen Sie, dass Sie diesen Hinweis gelesen und verstanden haben.